CNIPA

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

Retrieved on: 
Tuesday, March 26, 2024
Research, Legal, Medical Devices, Patent Law, Genetics, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Trade, CVC, Patent, RNA, CNIPA, Emmanuelle, University, Genomics, CRISPR, Eukaryote, Intellectual property, Cas9

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.
  • The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.
  • The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio.

TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

Retrieved on: 
Wednesday, February 21, 2024
Research, Infectious Diseases, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Maker, Therapy, Messenger, CIPO, Vaccine, General counsel, ARCA, COVID-19, SaRNA, CNIPA, Intellectual property, Melamaravakkadu, Human

“mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.

Key Points: 
  • “mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.
  • CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines.
  • “TriLink’s CleanCap technology is helping to bring life-saving therapeutics and vaccines to market faster,” added Kurt Oreshack, Executive Vice President & General Counsel, Maravai LifeSciences.
  • “These additional jurisdictions fortify the validity and strength of our global intellectual property.”
    Last May, TriLink launched its most robust analog to date: CleanCap® M6 .

XTI Aircraft Company Receives Expanded Patent from China

Retrieved on: 
Monday, February 12, 2024
Aircraft, XTI, CNIPA, Patent

ENGLEWOOD, Colo., Feb. 12, 2024 /PRNewswire/ -- XTI Aircraft Company ("XTI" or "Company"), announced today that the China National Intellectual Property Administration (CNIPA) has issued a new utility patent for the Company related to the TriFan 600, an innovative, fixed-wing, vertical takeoff and landing (VTOL) aircraft currently in development. Generally, the patent covers certain aspects of the TriFan's pivoting ducted fans that rotate between vertical lift and horizontal thrust, which, in turn, are designed to enable the TriFan 600 to transition from vertical takeoff to forward cruise. China is one of the fastest-growing aerospace markets (source), and Boeing estimates China will become the biggest domestic aviation market in the world in the next two decades (source).

Key Points: 
  • ENGLEWOOD, Colo., Feb. 12, 2024 /PRNewswire/ -- XTI Aircraft Company ("XTI" or "Company"), announced today that the China National Intellectual Property Administration (CNIPA) has issued a new utility patent for the Company related to the TriFan 600, an innovative, fixed-wing, vertical takeoff and landing (VTOL) aircraft currently in development.
  • China is one of the fastest-growing aerospace markets ( source ), and Boeing estimates China will become the biggest domestic aviation market in the world in the next two decades ( source ).
  • "The new patent represents an expansion of the scope of the patent that China originally granted to XTI in September 2019," said Scott Pomeroy, chief financial officer of XTI and future chief executive officer of the combined company which will result from the XTI and Inpixon merger .
  • As a result of this issuance, the scope of our Chinese patent matches the patent protection that we have for the TriFan 600 in the U.S., Europe, and other countries.

Everything Blockchain Inc. Poised for Growth in 2024

Retrieved on: 
Monday, February 12, 2024
Blockchain, OEM, Encryption, Internet, ADFS, Patent, Computer security, ESG, Zero trust security model, ART, FIDO, Fintech, IP, Pocs, EBI, CNIPA, SAML, Artificial intelligence, DBMS, Active Directory, Cryptocurrency

Performance testing showed up to 4x better performance against the competition and up to 40% cost savings.

Key Points: 
  • Performance testing showed up to 4x better performance against the competition and up to 40% cost savings.
  • In addition, by adding the ability to store embeddings and vectors, BuildDB is now able to displace traditional vector databases in AI applications.
  • We look forward to 2024 being a significant growth year as our platforms launch into the market and we acquire important customers.
  • To learn more about Everything Blockchain Inc, visit https://everythingblockchain.io/

RealD Wins All Three Patent Invalidation Challenges against Its 3D Projection Cinema Systems and Maintains All Three Invention Patents in China

Retrieved on: 
Wednesday, January 24, 2024
European Patent Convention, EPO, RealD, CNIPA, 3D, Partnership, Shenzhen, RealD 3D, Intellectual property, Patent

LOS ANGELES, Jan. 24, 2024 /PRNewswire/ -- Global visual technology leader RealD Inc. announced today that the China National Intellectual Property Office (CNIPA) has ruled in favor of RealD, rejecting all three Shenzhen LeVision Global Technology Co., Ltd.'s requests to invalidate RealD's Chinese patents.  LeVision's three invalidity challenges to the RealD 3D® dual-beam and the three-beam optical system patents were all rejected, confirming in full the validity and integrity of the invention patents of RealD 3D® projection system in China.

Key Points: 
  • LeVision's three invalidity challenges to the RealD 3D® dual-beam and the three-beam optical system patents were all rejected, confirming in full the validity and integrity of the invention patents of RealD 3D® projection system in China.
  • These patent challenges are the second time an individual or company has filed an invalidation request against patents owned by RealD 3D® regarding their three-beam optical technology in China.
  • In 2018, the European Patent Office (EPO) rejected both Volfoni and MasterImage's European patent invalidation challenges against RealD, and the validity, scope, and rights of RealD 3D® system remained unchanged.
  • Since its introduction, the RealD 3D system has become the world's most widely used cinema 3D projection technology.

LUMINELLE Announces China National Intellectual Property Administration’s Decision to Grant Issuance of Patent for LUMINELLE Bx (Biopsy) System, Expanding Global Footprint

Retrieved on: 
Thursday, October 5, 2023
Oncology, Medical Devices, Health, Consumer, Women, Biotechnology, Patent, Cancer, Food, China National Intellectual Property Administration, American Society of Clinical Oncology, CNIPA, Death, Mortality, Disease, Uterine cancer, Anesthesia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chinese patent medicine, Woman, Medical imaging, Biopsy

LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.

Key Points: 
  • LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.
  • 201880086268.8 titled “Biopsy Device and Method” for the LUMINELLE Bx System.
  • Issued on September 22, 2023, the new patent provides LUMINELLE with international intellectual property rights and allows the company to expand its technological footprint beyond the U.S. borders.
  • “The patent issuance from the CNIPA is a significant milestone for LUMINELLE as we continue to develop life-changing diagnostics for women everywhere,” said LUMINELLE CEO Allison London Brown.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023
GMP, China National Intellectual Property Administration, Patent, Antigen, CNIPA, Partnership, IPSC, NKT, STAR, National University Hospital, Clinical trial, Cell, Immunotherapy, CN, NUH, Agency for Science, Technology and Research, Hematological Cancer Research Investment and Education Act, Biological patents in the United States, Risk, A*STAR, Cytomics, Blood, Agency, Cancer, Same, Outline of health sciences, Health Sciences Authority, T, HSA, NKG2D, Pharmaceutical industry, Vaccine, Science, Research

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

South Rampart Pharma Further Expands Patent Portfolio for SRP-001 with Composition of Matter Patent in China

Retrieved on: 
Thursday, July 6, 2023
China National Intellectual Property Administration, Patent, CNIPA, Chinese patent medicine, United States Patent and Trademark Office, European Patent Office, IP, EPO, Pain, Paracetamol, European Patent Convention, Liver, Chronic pain, Pharmaceutical industry

NEW ORLEANS, July 6, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart's novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen. The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial. This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart's global intellectual property (IP) and patent strategy.

Key Points: 
  • The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial.
  • This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart's global intellectual property (IP) and patent strategy.
  • South Rampart Pharma's novel non-opioid global portfolio now includes granted patents in U.S. and Asia-Pacific territories.
  • Furthermore, regarding the Company's IP strategy in Europe, South Rampart has recently been notified by the European Patent Office (EPO) that the European patent application for SRP-001 has been allowed.

Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Retrieved on: 
Wednesday, June 21, 2023
China National Intellectual Property Administration, Patent, Allergy, CNIPA, Food, Diet, IPad, Artificial intelligence, Safety, Algorithm, Patient, IBS, Chinese patent medicine, Environment, Dietary supplement, Medical device, Pharmaceutical industry

The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient's medical data.

Key Points: 
  • The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient's medical data.
  • The technology could also recommend alternative packaged or prepared foods that do not contain the previously identified harmful food ingredient.
  • This patent further strengthens the Company’s robust intellectual property portfolio in the area of science, diet and technology.
  • The allowed patent application number in China is 201680054790.9 and can be viewed at: https://biomerica.com/inFoods/our-technology/

Sunrise New Energy Granted Five Patents for Technological Breakthroughs in Silicon Anode Manufacturing

Retrieved on: 
Thursday, June 15, 2023
Intellectual, China National Intellectual Property Administration, Intellectual property, CNIPA, Way, Research, Carbon, Invention, EPOW, Silicon, Lithium

ZIBO, China, June 15, 2023 (GLOBE NEWSWIRE) -- Sunrise New Energy Co., Ltd. (“Sunrise New Energy”, the “Company”, “we” or “our”) (NASDAQ: EPOW), today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company five patents, marking significant advancements in the field of silicon anode manufacturing. These patents reinforce the Company's commitment to innovation and position it at the forefront of next-generation lithium-ion battery technology.

Key Points: 
  • AJ220008f-1B Sunrise (Guizhou) New Energy Materials Co. 2017111552502: A lithium-ion battery, silicon carbon cathode material used and its preparation method.
  • AJ220018f-1 Sunrise (Guizhou) New Energy Materials Co. 2022103961109: A fast ion conductor clad silicon carbon composite material and its preparation method.
  • These patents, granted by the China National Intellectual Property Administration (CNIPA), represent significant technological breakthroughs achieved by the Company in the realm of silicon anode manufacturing.
  • The newly granted patents join the Company's growing portfolio of intellectual property, which already includes patents covering graphite anode materials and advanced manufacturing processes.